![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials.
Financial and competing interests disclosure
L Aronne is consultant/ resides on the advisory board for Jamieson Laboratories, Pfizer, Novo Nordisk, Eisai, Vivus Inc, GI Dynamics, Jovia Health, Takeda and Gelesis. He is a shareholder of Zafgen, Gelesis, Myos Corp and Jamieson Labs. He sits on the Board of Directors for Myos Corp and Jamieson Laboratories and has received research funding from Aspire Bariatrics and Eisai. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.